New shot aims to train immune system against Hard-to-Treat breast cancer
NCT ID NCT06746688
First seen May 06, 2026 · Last updated May 06, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called ES2B-C001, given alone or with an adjuvant, in 40 adults with HER2-positive metastatic breast cancer that has not responded to at least two prior therapies. The goal is to see if it is safe and can boost the immune system to fight the cancer. This is a first-in-human study, so the main focus is on safety and finding the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University Of Vienna
RECRUITINGVienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Medical University of Graz
RECRUITINGGraz, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ordensklinikum Linz GmbH Barmherzige Schwestern
RECRUITINGLinz, 4010, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.